How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

640 results for

aspirin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Health Information Technology: Text Messaging Interventions for Medication Adherence Among Patients with Chronic Diseases

Couns 2014;94(2):261–8. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS 2011;25(6): 825–34. *Quilici J, Fugon L, Beguin S, et al. Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. Int J Cardiol 2013;168(1): 568–9. *Strandbygaard U, Thomsen SF, Backer V

2017 Community Preventive Services Task Force

102. Cardiovascular Disease: Mobile Health (mHealth) Interventions for Treatment Adherence among Newly Diagnosed Patients

of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronarysyndrome. Int J Cardiol 2013; 168: 568-9. Varnfield M, Karunanithi M, Lee CK, et al. Smartphone-based home care model improved use of cardiac rehabilitation in post myocardial infarction patients: results from a randomized controlled trial. Heart 2014; 100: 1770-9. Widmer RJ, Allison T, Lerman L, Lerman A. The augmentation of usual cardiac rehabilitation with an online and smartphone-based program

2017 Community Preventive Services Task Force

103. Diabetes Management: Interventions Engaging Community Health Workers

" OR "diets" OR "dieting" OR alcohol* OR "aspirin" OR adher* OR "cardiovascular disease" or "cardiovascular diseases" or "comprehensive CVD risk reduction" OR "comprehensive cardiovascular disease risk reduction" OR "chronic disease" OR "chronic diseases") OR MH "Chronic Disease" OR MH "Patient Compliance+" OR MH "Medication Compliance" OR MH "Aspirin" OR MH "Alcoholic Intoxication" OR MH "Alcoholism" OR MH "Alcohol Rehabilitation Programs+" OR MH "Ethanol+" OR MH "Alcohol-Induced Disorders, Nervous (...) or physical activity or tobacco or nutrition or diet or alcohol or aspirin or adherence or comprehensive CVD risk reduction or chronic disease or cardiovascular disease or cardiovascular diseases:ti,ab,kw [Word variations have been searched] #3 #1 and #2 #4 Team-based care or integrated care or coordinated care or collaborative care or primary care teams or navigator or liaison or screening or education or outreach or home visits or enroll or community organizer or community development or health advocacy

2017 Community Preventive Services Task Force

107. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update

postoperative VTE, major bleeding, and other adverse events. We conducted pairwise meta-analyses, Bayesian network meta-analyses, and strength of evidence (SoE) synthesis. Results. Overall, 127 RCTs and 15 NRCSs met criteria. For THR: low molecular weight heparin (LMWH) has lower risk than unfractionated heparin (UFH) of various VTE outcomes (moderate to high SoE) and major bleeding (moderate SoE). LMWH and aspirin have similar risks of total PE, symptomatic DVT, and major bleeding (low SoE). LMWH has less (...) lower risk of various VTE outcomes (low to moderate SoE). For HFx surgery: LMWH has lower total DVT risk than FXaI (moderate SoE). Conclusions. VTE prophylaxis after major orthopedic surgery trades off lowered VTE risk with possible adverse events—in particular, for most interventions, major bleeding. In THR, LMWH has lower VTE and adverse event risks than UFH, LMWH and aspirin have similar risks of VTE and major bleeding, DTI has lower DVT risk than LMWH but higher major bleeding risk, and higher

2017 Effective Health Care Program (AHRQ)

111. P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. (Abstract)

, in the Randomized Trial to Compare the Safety of Rivaroxaban vs Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome (GEMINI-ACS-1) clinical trial.The GEMINI-ACS-1 trial compared rivaroxaban, 2.5 mg twice daily, with aspirin, 100 mg daily, plus open-label clopidogrel or ticagrelor (provided), in patients with recent acute coronary syndromes (ACS). The trial included 371 clinical centers in 21 countries and 3037 patients with ACS. Data were analyzed between May 2017 and February

2019 JAMA cardiology Controlled trial quality: uncertain

112. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. Full Text available with Trip Pro

therapy will produce the predefined cut-off of platelet inhibition measured using the Multiplate test in COPD patients. Eligible patients were randomised to aspirin plus placebo, ticagrelor plus placebo, aspirin plus ticagrelor or placebo only for 6 months. The primary outcome comprises inhibition (binary response) of arachidonic acid- (ASPI test, cut-off <40) and adenosine diphosphate- (ADP test, cut-off <46) induced platelet aggregation at 6 months. 543 patients were screened and 120 patients were (...) recruited with mean age of 67.5 years; 47.5% patients were male. The per-protocol ASPI test response rate to aspirin was 68.3% (95% CI 52.3-80.9%). The per-protocol ADP test response rate to ticagrelaor was 68.8% (95% CI 50.4-82.6%). Platelet response to antiplatelet therapy with aspirin and ticagrelor was not observed in nearly one-third of COPD patients without prior history of cardiovascular disease. These findings support the high pro-thrombotic milieu and the need for further research to determine

2019 ERJ open research Controlled trial quality: predicted high

113. Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. Full Text available with Trip Pro

Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. There is debate on whether the beneficial effect of implantable cardioverter-defibrillators (ICDs) is attenuated in patients with non-ischaemic cardiomyopathy (NICM). We assess whether any ICD benefit differs between patients with NICM and those with ischaemic cardiomyopathy (ICM), using data from the Warfarin versus Aspirin in Reduced

2019 ESC heart failure Controlled trial quality: uncertain

114. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Full Text available with Trip Pro

0.33, 95% CI 0.14 to 0.83), while the difference between LMWH and aspirin was not statistically significant (RR 0.51, 95% CI 0.22 to 1.17). Major bleeding was observed in none of the participants treated with LMWH or warfarin and in less than 1% of those treated with aspirin. Only one study evaluated unfractionated heparin against no thromboprophylaxis but did not report on VTE or major bleeding. When compared with placebo, warfarin was associated with a non-statistically significant reduction

2016 Cochrane

115. Single dose dipyrone (metamizole) for acute postoperative pain in adults. Full Text available with Trip Pro

), and intramuscular dipyrone 2000 mg (35 participants) with placebo (236 participants). In addition to placebo, all studies used active controls (ibuprofen, paracetamol, aspirin, flurbiprofen, ketoprofen; 338 participants). Seven studies used the oral route of administration, and one study used the intramuscular route. The mean age ranged from 23 to 62 years. Six studies included both men and women, and two studies included only women. All the studies were small, but were otherwise of moderate to good

2016 Cochrane

116. Pharmacological treatment for Buerger's disease. (Abstract)

literature; screened reference lists of relevant studies, and contacted study authors and major pharmaceutical companies.Randomised controlled trials (RCTs) involving pharmacological agents used in the treatment of Buerger's disease.Two review authors, independently assessed the studies, extracted data and performed data analysis.Five randomised controlled trials (total 602 participants) compared prostacyclin analogue with placebo, aspirin, or a prostaglandin analogue, and folic acid with placebo (...) . No studies assessed other pharmacological agents such as cilostazol, clopidogrel and pentoxifylline or compared oral versus intravenous prostanoid.Compared with aspirin, intravenous prostacyclin analogue iloprost improved ulcer healing (risk ratio (RR) 2.65; 95% confidence interval (CI) 1.15 to 6.11; 98 participants; one study; moderate quality evidence), and helped to eradicate rest pain after 28 days (RR 2.28; 95% CI 1.48 to 3.52; 133 participants; one study; moderate quality evidence), although

2016 Cochrane

117. Sulodexide for treating venous leg ulcers. (Abstract)

, aspirin), with or without compression therapy.We used standard Cochrane methodological procedures. The authors independently selected studies, extracted data and assessed risk of bias. We pooled data to present the risk ratio (RR) with 95% confidence interval (CI), or presented a narrative summary. We assessed overall evidence quality according to the GRADE approach.We included four RCTs with a total of 463 participants (aged 42 years to 93 years); one report was only available as a published

2016 Cochrane

118. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. Full Text available with Trip Pro

Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. Morbidity in patients with chronic heart failure is high, and this predisposes them to thrombotic complications, including stroke and thromboembolism, which in turn contribute to high mortality. Oral anticoagulants (e.g. warfarin) and antiplatelet agents (e.g. aspirin) are the principle oral antithrombotic agents. Many heart failure patients with sinus rhythm take aspirin because coronary artery (...) Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal apps.who.int/trialsearch/) (searched in July 2016).We included randomised controlled trials comparing antiplatelet therapy versus oral anticoagulation in adults with chronic heart failure in sinus rhythm. Treatment had to last at least one month. We compared orally administered antiplatelet agents (aspirin, ticlopidine, clopidogrel, prasugrel, ticagrelor, dipyridamole) versus anticoagulant agents (coumarins, warfarin

2016 Cochrane

119. Pharmacological treatment for Buerger's disease. Full Text available with Trip Pro

literature; screened reference lists of relevant studies, and contacted study authors and major pharmaceutical companies.Randomised controlled trials (RCTs) involving pharmacological agents used in the treatment of Buerger's disease.Two review authors, independently assessed the studies, extracted data and performed data analysis.Five randomised controlled trials (total 602 participants) compared prostacyclin analogue with placebo, aspirin, or a prostaglandin analogue, and folic acid with placebo (...) . No studies assessed other pharmacological agents such as cilostazol, clopidogrel and pentoxifylline or compared oral versus intravenous prostanoid.Compared with aspirin, intravenous prostacyclin analogue iloprost improved ulcer healing (risk ratio (RR) 2.65; 95% confidence interval (CI) 1.15 to 6.11; 98 participants; one study; moderate quality evidence), and helped to eradicate rest pain after 28 days (RR 2.28; 95% CI 1.48 to 3.52; 133 participants; one study; moderate quality evidence), although

2016 Cochrane

120. Pentoxifylline for intermittent claudication. Full Text available with Trip Pro

on duration and dose of pentoxifylline.We included in this review 24 studies with 3377 participants. Seventeen studies compared pentoxifylline versus placebo. In the seven remaining studies, pentoxifylline was compared with flunarizine (one study), aspirin (one study), Gingko biloba extract (one study), nylidrin hydrochloride (one study), prostaglandin E1 (two studies) and buflomedil and nifedipine (one study). The quality of the evidence was generally low, with large variability in reported findings

2015 Cochrane

Systematic Reviews (Non-Premium)

Systematic reviews are arguably the most important way of telling if an intervention is worthwhile.  As a FREE user you have access to 100,000 less systematic reviews than a Pro user.  Upgrade today.